As a result, therapies targeting the AR pathway, such as next-generation AR antagonists and agents that inhibit androgen biosynthesis, remain the cornerstone of CRPC management, emphasizing the clinical importance of AR in the resistance and evolution of advanced prostate cancer. This evidence concerns the gene AR and prostate cancer.